Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment
Tomohiro Yabushita(The University of Tokyo), Susumu Goyama(The University of Tokyo), Makoto Nakanishi(The Cancer Institute Hospital), Keiko Kato(Yamagata University), Tatsuo Fukagawa(The University of Osaka), Tomoyoshi Soga(Keio University), Toshio Kitamura(National Agriculture and Food Research Organization), Shuhei Asada(The University of Tokyo), Tomoya Isobe(Wellcome/MRC Cambridge Stem Cell Institute), Yasuhito Nannya(Kyoto University), Daiju Kitagawa(National Institute of Genetics), Yutaka Enomoto(The University of Tokyo), Tomofusa Fukuyama(The University of Tokyo), Atsuya Nishiyama(The University of Tokyo), Ruka Shimura(The University of Tokyo), Yosuke Tanaka(University of Occupational and Environmental Health Japan), Naru Sato(The University of Tokyo), Keita Yamamoto(The University of Tokyo), Hitoshi Satoh(The University of Tokyo), Takamasa Ishikawa(Keio University), Kaori Saitoh(Yamagata University), Takumi Chinen(National Institute of Genetics)
Cited by 28
Related Papers
MassBank: a public repository for sharing mass spectral data for life sciences
|Journal of Mass Spectrometry|2010|2.6k
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
|Nature Medicine|2019|1.5k
Navigating the DNA methylation landscape of cancer
|Trends in Genetics|2021|1k